OncLive | Positive Idelalisib Data Halts Late-Stage CLL Trial OncLive A phase III study of the PI3K-delta inhibitor idelalisib in combination with rituximab (Rituxan) has been stopped early following a positive interim analysis, according to a statement from Gilead Sciences, Inc., the company developing the drug. The ... Gilead Climbs on More Good News for Cancer Drug From Seattle Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic Leukemia ... Gilead halts leukaemia study on positive results |
